Press News

Press News

Press News | 01.04.2024

Print:
Title Media Publication Date
Clinical Trials “once a month” Kathimerini 30/03/2024
How do population changes affect the economy? Naftemporiki 01/04/2024
In shortage 15 antimicrobial medicines Proto Thema 31/03/2024
Changes in pharmaceutical policy by the MoH Ta Nea 01/04/2024
Investments of 1.2 billion euros in the period 2020-2026 Ta Nea 01/04/2024
Why young doctors avoid the NHS To Vima 31/03/2024

 

See here the publicity report

 

Web Monitoring Report for the period 29/03 – 01/04

Title Media Publication Date
What are the three new pharmaceutical plants being prepared in Tripoli? capital.gr 01/04/2024
The liquidation of AMKAs begins: Who loses the free medical care iatropedia.gr 01/04/2024
The Greek Pharmaceutical Industry “bets” in Tripoli – New investment insider.gr 01/04/2024
Misleading information about the cervical cancer prevention program moh.gov.gr 01/04/2024
Rationalization of pharmaceutical expenditure and changes in low-cost medicines moneyreview.gr 30/03/2024
Georgiadis: The goal of clawback control is patient survival news4health.gr 30/03/2024
Clinical trials: Acceleration of procedures through the Ethics Committee news4health.gr 30/03/2024
EOPE: The use of oncological medicines is done in a rational way newsbomb.gr 01/04/2024
Georgiadis: Control of pharmaceutical expenditure through the oncology councils of the hospitals newsbomb.gr 30/03/2024
EOPYY: What does digital transformation include? ot.gr 30/03/2024
Vassilis Kontozamanis: Greece’s healthcare sector sees growth across 5 key areas parapolitika.gr 30/03/2024
Innovative medicines and investments in the service of the patient ygeiamou.gr 01/04/2024

RELATED NEWS

Skip to content
SFEE
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.